An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis
Butyrate has been shown to be effective in ulcerative colitis (UC). However, its oral administration is rare due to its rancid odour and unpleasant taste. In this study, the effect of a butyrate-releasing polysaccharide derivative, xylan butyrate ester (XylB), was evaluated in a dextran sodium sulph...
Gespeichert in:
| Veröffentlicht in: | International journal of biological macromolecules 2020-08, Vol.156, p.1217-1233 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1233 |
|---|---|
| container_issue | |
| container_start_page | 1217 |
| container_title | International journal of biological macromolecules |
| container_volume | 156 |
| creator | Zha, Zhengqi Lv, Yang Tang, Huiling Li, Tingting Miao, Yinghua Cheng, Junwei Wang, Guoqing Tan, Yanfang Zhu, Yan Xing, Xiao Ding, Kang Wang, Ying Yin, Hongping |
| description | Butyrate has been shown to be effective in ulcerative colitis (UC). However, its oral administration is rare due to its rancid odour and unpleasant taste. In this study, the effect of a butyrate-releasing polysaccharide derivative, xylan butyrate ester (XylB), was evaluated in a dextran sodium sulphate (DSS)-induced UC model in C57BL/6 mice. Linear xylan was extracted from corn cobs. The C-2 and C-3 positions of the linear xylan were esterified with butyrate, forming XylB. The protective and therapeutic effects of XylB against UC were determined in a DSS-induced mouse model. The results showed that XylB treatments reversed the imbalance between pro- and anti-inflammatory cytokines. Moreover, XylB rebalanced the gut microbiota that interfered with DSS treatment and significantly decreased the relative abundance of the genera Oscillibacter, Ruminococcaceae UCG-009, Erysipelatoclostridium, and Defluviitaleaceae UCG-01. XylB increased butyrate content in the colon, upregulated G-protein coupled receptor 109A protein expression, inhibited histone deacetylase (HDAC) activity, and exerted anti-inflammatory activity through autophagy pathway activation and nuclear factor-κB (NF-κB) inhibition. XylB reduces inflammatory intestinal damage in mice, suggesting that it would be a potential drug for the treatment of UC and could be used to overcome the limitations of the oral administration of sodium butyrate. |
| doi_str_mv | 10.1016/j.ijbiomac.2019.11.159 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_webof</sourceid><recordid>TN_cdi_webofscience_primary_000538104200121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0141813019373003</els_id><sourcerecordid>31759015</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-1982d65334375a45e1efb1a97415924052ae3b43af6cea1899301bafa4ca23f83</originalsourceid><addsrcrecordid>eNqNkE2P0zAQQC0EYsvCX1j5jhI8cZI6N1YVX9JKXOBsOfYEpkrsynbK9sg_x6W7e4WT5dF7I81j7AZEDQL6d_ua9iOFxdi6ETDUADV0wzO2AbUdKiGEfM42AlqoFEhxxV6ltC_TvgP1kl1J2HaDgG7Dft96HqKZ5xM3biFPKWNEx8c1n6LJWEWc0STyP_j9aTaeO4x0NJmOyAu3Wkyc_DSbZSnD4MunIPc5FjSt8-Fn2cFTcLQuFfkz7_iyRvLIbZgpU3rNXkxmTvjm4b1m3z9--Lb7XN19_fRld3tXWdmrXMGgGtd3UrZy25m2Q8BpBDNs23J304quMSjHVpqpt2hADYMUMJrJtNY0clLymvWXvTaGlCJO-hBpMfGkQehzU73Xj031uakG0GV3EW8u4mEdF3RP2mPEAry9AL9wDFOyhN7iE1aqd1KBaBshoIFCq_-nd5T_Zt2F1eeivr-oWDodCaN-0B1FtFm7QP865g-62q_i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zha, Zhengqi ; Lv, Yang ; Tang, Huiling ; Li, Tingting ; Miao, Yinghua ; Cheng, Junwei ; Wang, Guoqing ; Tan, Yanfang ; Zhu, Yan ; Xing, Xiao ; Ding, Kang ; Wang, Ying ; Yin, Hongping</creator><creatorcontrib>Zha, Zhengqi ; Lv, Yang ; Tang, Huiling ; Li, Tingting ; Miao, Yinghua ; Cheng, Junwei ; Wang, Guoqing ; Tan, Yanfang ; Zhu, Yan ; Xing, Xiao ; Ding, Kang ; Wang, Ying ; Yin, Hongping</creatorcontrib><description>Butyrate has been shown to be effective in ulcerative colitis (UC). However, its oral administration is rare due to its rancid odour and unpleasant taste. In this study, the effect of a butyrate-releasing polysaccharide derivative, xylan butyrate ester (XylB), was evaluated in a dextran sodium sulphate (DSS)-induced UC model in C57BL/6 mice. Linear xylan was extracted from corn cobs. The C-2 and C-3 positions of the linear xylan were esterified with butyrate, forming XylB. The protective and therapeutic effects of XylB against UC were determined in a DSS-induced mouse model. The results showed that XylB treatments reversed the imbalance between pro- and anti-inflammatory cytokines. Moreover, XylB rebalanced the gut microbiota that interfered with DSS treatment and significantly decreased the relative abundance of the genera Oscillibacter, Ruminococcaceae UCG-009, Erysipelatoclostridium, and Defluviitaleaceae UCG-01. XylB increased butyrate content in the colon, upregulated G-protein coupled receptor 109A protein expression, inhibited histone deacetylase (HDAC) activity, and exerted anti-inflammatory activity through autophagy pathway activation and nuclear factor-κB (NF-κB) inhibition. XylB reduces inflammatory intestinal damage in mice, suggesting that it would be a potential drug for the treatment of UC and could be used to overcome the limitations of the oral administration of sodium butyrate.</description><identifier>ISSN: 0141-8130</identifier><identifier>EISSN: 1879-0003</identifier><identifier>DOI: 10.1016/j.ijbiomac.2019.11.159</identifier><identifier>PMID: 31759015</identifier><language>eng</language><publisher>AMSTERDAM: Elsevier B.V</publisher><subject>Administration, Oral ; Animals ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - chemistry ; Anti-Inflammatory Agents - pharmacology ; Anti-Inflammatory Agents - therapeutic use ; Autophagy ; Autophagy - drug effects ; Biochemistry & Molecular Biology ; Butyrates - metabolism ; Carbohydrate Sequence ; Chemistry ; Chemistry, Applied ; Colitis - drug therapy ; Colitis - immunology ; Colitis - metabolism ; Colon - drug effects ; Colon - immunology ; Colon - metabolism ; Dextran Sulfate - adverse effects ; Gut microbiota ; HDAC ; Life Sciences & Biomedicine ; Mice ; Mice, Inbred C57BL ; NF-κB ; Physical Sciences ; Polymer Science ; Science & Technology ; T-Lymphocytes, Regulatory - drug effects ; Th17 Cells - drug effects ; Ulcerative colitis ; xylan butyrate ester ; Xylans - administration & dosage ; Xylans - chemistry ; Xylans - pharmacology ; Xylans - therapeutic use</subject><ispartof>International journal of biological macromolecules, 2020-08, Vol.156, p.1217-1233</ispartof><rights>2019</rights><rights>Copyright © 2019. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>63</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000538104200121</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c368t-1982d65334375a45e1efb1a97415924052ae3b43af6cea1899301bafa4ca23f83</citedby><cites>FETCH-LOGICAL-c368t-1982d65334375a45e1efb1a97415924052ae3b43af6cea1899301bafa4ca23f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijbiomac.2019.11.159$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31759015$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zha, Zhengqi</creatorcontrib><creatorcontrib>Lv, Yang</creatorcontrib><creatorcontrib>Tang, Huiling</creatorcontrib><creatorcontrib>Li, Tingting</creatorcontrib><creatorcontrib>Miao, Yinghua</creatorcontrib><creatorcontrib>Cheng, Junwei</creatorcontrib><creatorcontrib>Wang, Guoqing</creatorcontrib><creatorcontrib>Tan, Yanfang</creatorcontrib><creatorcontrib>Zhu, Yan</creatorcontrib><creatorcontrib>Xing, Xiao</creatorcontrib><creatorcontrib>Ding, Kang</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Yin, Hongping</creatorcontrib><title>An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis</title><title>International journal of biological macromolecules</title><addtitle>INT J BIOL MACROMOL</addtitle><addtitle>Int J Biol Macromol</addtitle><description>Butyrate has been shown to be effective in ulcerative colitis (UC). However, its oral administration is rare due to its rancid odour and unpleasant taste. In this study, the effect of a butyrate-releasing polysaccharide derivative, xylan butyrate ester (XylB), was evaluated in a dextran sodium sulphate (DSS)-induced UC model in C57BL/6 mice. Linear xylan was extracted from corn cobs. The C-2 and C-3 positions of the linear xylan were esterified with butyrate, forming XylB. The protective and therapeutic effects of XylB against UC were determined in a DSS-induced mouse model. The results showed that XylB treatments reversed the imbalance between pro- and anti-inflammatory cytokines. Moreover, XylB rebalanced the gut microbiota that interfered with DSS treatment and significantly decreased the relative abundance of the genera Oscillibacter, Ruminococcaceae UCG-009, Erysipelatoclostridium, and Defluviitaleaceae UCG-01. XylB increased butyrate content in the colon, upregulated G-protein coupled receptor 109A protein expression, inhibited histone deacetylase (HDAC) activity, and exerted anti-inflammatory activity through autophagy pathway activation and nuclear factor-κB (NF-κB) inhibition. XylB reduces inflammatory intestinal damage in mice, suggesting that it would be a potential drug for the treatment of UC and could be used to overcome the limitations of the oral administration of sodium butyrate.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - chemistry</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Autophagy</subject><subject>Autophagy - drug effects</subject><subject>Biochemistry & Molecular Biology</subject><subject>Butyrates - metabolism</subject><subject>Carbohydrate Sequence</subject><subject>Chemistry</subject><subject>Chemistry, Applied</subject><subject>Colitis - drug therapy</subject><subject>Colitis - immunology</subject><subject>Colitis - metabolism</subject><subject>Colon - drug effects</subject><subject>Colon - immunology</subject><subject>Colon - metabolism</subject><subject>Dextran Sulfate - adverse effects</subject><subject>Gut microbiota</subject><subject>HDAC</subject><subject>Life Sciences & Biomedicine</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>NF-κB</subject><subject>Physical Sciences</subject><subject>Polymer Science</subject><subject>Science & Technology</subject><subject>T-Lymphocytes, Regulatory - drug effects</subject><subject>Th17 Cells - drug effects</subject><subject>Ulcerative colitis</subject><subject>xylan butyrate ester</subject><subject>Xylans - administration & dosage</subject><subject>Xylans - chemistry</subject><subject>Xylans - pharmacology</subject><subject>Xylans - therapeutic use</subject><issn>0141-8130</issn><issn>1879-0003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkE2P0zAQQC0EYsvCX1j5jhI8cZI6N1YVX9JKXOBsOfYEpkrsynbK9sg_x6W7e4WT5dF7I81j7AZEDQL6d_ua9iOFxdi6ETDUADV0wzO2AbUdKiGEfM42AlqoFEhxxV6ltC_TvgP1kl1J2HaDgG7Dft96HqKZ5xM3biFPKWNEx8c1n6LJWEWc0STyP_j9aTaeO4x0NJmOyAu3Wkyc_DSbZSnD4MunIPc5FjSt8-Fn2cFTcLQuFfkz7_iyRvLIbZgpU3rNXkxmTvjm4b1m3z9--Lb7XN19_fRld3tXWdmrXMGgGtd3UrZy25m2Q8BpBDNs23J304quMSjHVpqpt2hADYMUMJrJtNY0clLymvWXvTaGlCJO-hBpMfGkQehzU73Xj031uakG0GV3EW8u4mEdF3RP2mPEAry9AL9wDFOyhN7iE1aqd1KBaBshoIFCq_-nd5T_Zt2F1eeivr-oWDodCaN-0B1FtFm7QP865g-62q_i</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Zha, Zhengqi</creator><creator>Lv, Yang</creator><creator>Tang, Huiling</creator><creator>Li, Tingting</creator><creator>Miao, Yinghua</creator><creator>Cheng, Junwei</creator><creator>Wang, Guoqing</creator><creator>Tan, Yanfang</creator><creator>Zhu, Yan</creator><creator>Xing, Xiao</creator><creator>Ding, Kang</creator><creator>Wang, Ying</creator><creator>Yin, Hongping</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20200801</creationdate><title>An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis</title><author>Zha, Zhengqi ; Lv, Yang ; Tang, Huiling ; Li, Tingting ; Miao, Yinghua ; Cheng, Junwei ; Wang, Guoqing ; Tan, Yanfang ; Zhu, Yan ; Xing, Xiao ; Ding, Kang ; Wang, Ying ; Yin, Hongping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-1982d65334375a45e1efb1a97415924052ae3b43af6cea1899301bafa4ca23f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - chemistry</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Autophagy</topic><topic>Autophagy - drug effects</topic><topic>Biochemistry & Molecular Biology</topic><topic>Butyrates - metabolism</topic><topic>Carbohydrate Sequence</topic><topic>Chemistry</topic><topic>Chemistry, Applied</topic><topic>Colitis - drug therapy</topic><topic>Colitis - immunology</topic><topic>Colitis - metabolism</topic><topic>Colon - drug effects</topic><topic>Colon - immunology</topic><topic>Colon - metabolism</topic><topic>Dextran Sulfate - adverse effects</topic><topic>Gut microbiota</topic><topic>HDAC</topic><topic>Life Sciences & Biomedicine</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>NF-κB</topic><topic>Physical Sciences</topic><topic>Polymer Science</topic><topic>Science & Technology</topic><topic>T-Lymphocytes, Regulatory - drug effects</topic><topic>Th17 Cells - drug effects</topic><topic>Ulcerative colitis</topic><topic>xylan butyrate ester</topic><topic>Xylans - administration & dosage</topic><topic>Xylans - chemistry</topic><topic>Xylans - pharmacology</topic><topic>Xylans - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zha, Zhengqi</creatorcontrib><creatorcontrib>Lv, Yang</creatorcontrib><creatorcontrib>Tang, Huiling</creatorcontrib><creatorcontrib>Li, Tingting</creatorcontrib><creatorcontrib>Miao, Yinghua</creatorcontrib><creatorcontrib>Cheng, Junwei</creatorcontrib><creatorcontrib>Wang, Guoqing</creatorcontrib><creatorcontrib>Tan, Yanfang</creatorcontrib><creatorcontrib>Zhu, Yan</creatorcontrib><creatorcontrib>Xing, Xiao</creatorcontrib><creatorcontrib>Ding, Kang</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Yin, Hongping</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>International journal of biological macromolecules</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zha, Zhengqi</au><au>Lv, Yang</au><au>Tang, Huiling</au><au>Li, Tingting</au><au>Miao, Yinghua</au><au>Cheng, Junwei</au><au>Wang, Guoqing</au><au>Tan, Yanfang</au><au>Zhu, Yan</au><au>Xing, Xiao</au><au>Ding, Kang</au><au>Wang, Ying</au><au>Yin, Hongping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis</atitle><jtitle>International journal of biological macromolecules</jtitle><stitle>INT J BIOL MACROMOL</stitle><addtitle>Int J Biol Macromol</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>156</volume><spage>1217</spage><epage>1233</epage><pages>1217-1233</pages><issn>0141-8130</issn><eissn>1879-0003</eissn><abstract>Butyrate has been shown to be effective in ulcerative colitis (UC). However, its oral administration is rare due to its rancid odour and unpleasant taste. In this study, the effect of a butyrate-releasing polysaccharide derivative, xylan butyrate ester (XylB), was evaluated in a dextran sodium sulphate (DSS)-induced UC model in C57BL/6 mice. Linear xylan was extracted from corn cobs. The C-2 and C-3 positions of the linear xylan were esterified with butyrate, forming XylB. The protective and therapeutic effects of XylB against UC were determined in a DSS-induced mouse model. The results showed that XylB treatments reversed the imbalance between pro- and anti-inflammatory cytokines. Moreover, XylB rebalanced the gut microbiota that interfered with DSS treatment and significantly decreased the relative abundance of the genera Oscillibacter, Ruminococcaceae UCG-009, Erysipelatoclostridium, and Defluviitaleaceae UCG-01. XylB increased butyrate content in the colon, upregulated G-protein coupled receptor 109A protein expression, inhibited histone deacetylase (HDAC) activity, and exerted anti-inflammatory activity through autophagy pathway activation and nuclear factor-κB (NF-κB) inhibition. XylB reduces inflammatory intestinal damage in mice, suggesting that it would be a potential drug for the treatment of UC and could be used to overcome the limitations of the oral administration of sodium butyrate.</abstract><cop>AMSTERDAM</cop><pub>Elsevier B.V</pub><pmid>31759015</pmid><doi>10.1016/j.ijbiomac.2019.11.159</doi><tpages>17</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0141-8130 |
| ispartof | International journal of biological macromolecules, 2020-08, Vol.156, p.1217-1233 |
| issn | 0141-8130 1879-0003 |
| language | eng |
| recordid | cdi_webofscience_primary_000538104200121 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Administration, Oral Animals Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - chemistry Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Autophagy Autophagy - drug effects Biochemistry & Molecular Biology Butyrates - metabolism Carbohydrate Sequence Chemistry Chemistry, Applied Colitis - drug therapy Colitis - immunology Colitis - metabolism Colon - drug effects Colon - immunology Colon - metabolism Dextran Sulfate - adverse effects Gut microbiota HDAC Life Sciences & Biomedicine Mice Mice, Inbred C57BL NF-κB Physical Sciences Polymer Science Science & Technology T-Lymphocytes, Regulatory - drug effects Th17 Cells - drug effects Ulcerative colitis xylan butyrate ester Xylans - administration & dosage Xylans - chemistry Xylans - pharmacology Xylans - therapeutic use |
| title | An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T06%3A55%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20orally%20administered%20butyrate-releasing%20xylan%20derivative%20reduces%20inflammation%20in%20dextran%20sulphate%20sodium-induced%20murine%20colitis&rft.jtitle=International%20journal%20of%20biological%20macromolecules&rft.au=Zha,%20Zhengqi&rft.date=2020-08-01&rft.volume=156&rft.spage=1217&rft.epage=1233&rft.pages=1217-1233&rft.issn=0141-8130&rft.eissn=1879-0003&rft_id=info:doi/10.1016/j.ijbiomac.2019.11.159&rft_dat=%3Cpubmed_webof%3E31759015%3C/pubmed_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31759015&rft_els_id=S0141813019373003&rfr_iscdi=true |